Immunic, a biotech firm developing oral therapies for neurologic diseases, announced its participation in key investor conferences in November, including Guggenheim, Stifel, and Jefferies Global Healthcare events. Executives will engage in fireside chats and one-on-one meetings with investors. Additionally, Immunic will host a virtual R&D day focused on progressive multiple sclerosis, featuring expert discussions on innovative treatment approaches. The company’s lead drug, vidofludimus calcium, is in Phase 3 trials for relapsing MS, with results expected by year-end 2026, and plans to start a Phase 3 trial for progressive MS later in the year.
Immunic's participation in November investor conferences is the subject here. For readers following the health sector, Pluang data shows that out of 150 priced US health stocks, 70 rose and 54 fell today. Notable movers include XRAY at USD 9.89 with a 3.78% increase, BNGO at USD 1.19 up 3.48%, and TWST at USD 157.77 rising 3.27%, as of Nov 02, 2026 18:12 WIB.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
